Introduction
Docetaxel belongs to the family of taxanes, a class of drugs that binds to microtubules and subsequently induces cell cycle arrest and apoptosis (1) . Docetaxel is widely used for systemic therapy of several solid malignancies, including lung cancer (2) . However, clinical failure of docetaxel therapy remains a major problem, and often patients are subjected to therapy-related toxicity without gaining benefit. As response to anticancer drugs is, at least in part, thought to depend on achieving sufficient drug levels in tumor tissue, assessment of docetaxel uptake in tumors in vivo may be useful to understand treatment failure in patients.
To this end, docetaxel was labeled with the short-lived positron emitting radionuclide carbon-11, resulting in [ 11 C]docetaxel with an identical molecular structure as the drug docetaxel itself (3, 4) . Using [ 11 C]docetaxel and positron emission tomography (PET), microdosing studies can be carried out to monitor pharmacokinetics and pharmacodynamics of docetaxel noninvasively in patients. In a previous safety study, [ 11 C]docetaxel showed high accumulation in liver (5, 6) , whereas concentrations in the chest were low (6) . These biodistribution data indicate that [ 11 C]docetaxel may be a suitable PET tracer for measuring docetaxel kinetics in thoracic tumors.
To assess whether a microdose [ 11 C]docetaxel scan can be used to predict response to docetaxel therapy, quantification of [ 11 C]docetaxel uptake in tumor tissue is needed. This, in turn, requires the development of a tracer kinetic model, describing tumor [ 11 C]docetaxel kinetics in relation to the time course in arterial plasma (delivery). Arterial blood sampling, however, is less suited for routine clinical studies. Dynamic PET scans of the chest provide the possibility to noninvasively generate an image derived input function (IDIF) based on the time course in, for example, the ascending aorta. As the accuracy of an ascending aorta IDIF depends on the biodistribution of a tracer, this procedure needs to be validated also for [ 11 C]docetaxel. Uptake of docetaxel in a tumor depends, at least in part, on its delivery through the circulation, which may be regulated by both drug exposure and tumor perfusion. Docetaxel exposure is reflected by clearance of [ 11 C]docetaxel from blood. Tumor perfusion can be measured using oxygen-15 labeled water ([ 15 O]H 2 O), which is a freely diffusible PET tracer (7) . Tumor size may also affect docetaxel delivery, as central necrotic areas with reduced tumor perfusion may develop with increasing tumor size (8) .
In addition, efflux pumps may affect the concentration of radiolabeled drugs in tumors. Docetaxel is a substrate for the efflux transporter ABCB1 (formerly known as P-glycoprotein or MDR1; ref. 9) . In this respect, the glucocorticoid dexamethasone, which is given as standard premedication to prevent several docetaxel-induced toxicities (10, 11) , is of particular interest, because dexamethasone is a potent inducer of this efflux transporter (12) . Accordingly, premedication with dexamethasone may affect docetaxel kinetics in tumors.
The primary objective of the present study was to evaluate the feasibility of quantitative PET studies with [ 11 C]docetaxel in patients with lung cancer. As mentioned above, this required development of the optimal tracer kinetic model for quantification of [ 11 C]docetaxel kinetics in lung cancer patients and validation of the use of a noninvasive procedure to enable implementation in routine clinical practice. The secondary objective was to explore whether [ 11 C]docetaxel kinetics were associated with tumor perfusion, tumor size, and administration of premedication with dexamethasone. Finally, as a limited number of patients were actually scheduled for docetaxel therapy, a preliminary assessment of the relationship between [ 11 C]docetaxel uptake and response to docetaxel therapy was possible.
Patients and Methods

Patients
Thirty-four patients (23 males and 11 females; median age 62 years; range 32-74 years) with advanced-stage cancer were prospectively enrolled prior to planned systemic therapy. Thirty-two patients were diagnosed with non-small cell lung cancer and two with malignant mesothelioma. Criteria for enrollment in the study were 18 years of age or older, a malignant lesion of at least 1.5 cm in diameter within the chest, life expectancy of at least 12 weeks, Karnofsky performance status scale >60%, thrombocyte count >100 Â 10 ), followed by 35 mL saline (rate 2 mLÁs
À1
). Data were normalized and all appropriate corrections were applied for dead time, decay, randoms, scatter, and attenuation. Using the 3-dimensional row action maximum likelihood reconstruction algorithm (3D RAMLA), 
Blood sampling
In the first 17 patients, arterial blood sampling was carried out during [ 11 C]docetaxel scanning. Using an online detection system (16), arterial blood was withdrawn continuously at a rate of 5 mLÁmin À1 during the first 5 minutes and 1.7 mLÁmin À1 thereafter. Twenty-nine minutes after injection, online sampling was discontinued to minimize the total amount of blood to be taken. In addition, both 10 mL arterial and venous samples were collected manually at 2.5, 5, 10, 15, 20, 30, 40, and 60 minutes postinjection. Prior to each sample, 3-5 mL blood was discarded and the line was flushed with 2 mL saline after each sample. Blood samples were analyzed for blood and plasma concentrations and potential radiolabeled metabolites of [ 11 C]docetaxel as described in the Supplementary Data.
Input functions
Blood sampler data of [ 11 C]docetaxel were corrected for delay relative to the time-activity curve of the ascending aorta. The resulting delay-corrected sampler curve was calibrated using the manually drawn arterial blood samples. Plasma/whole blood ratios derived from the manual blood samples were fitted to a sigmoid function. Finally, the blood sampler input function (BSIF) was obtained by multiplying the delay-corrected and calibrated sampler curve with this sigmoid function.
IDIFs (17) and it is considered to be a noninvasive alternative to arterial sampling. Hence, volumes of interest (VOI) of 1 cm diameter were drawn over the ascending aorta in approximately 10 consecutive image planes of the frame in which the first pass of the bolus was best visualized. Projection of these VOIs onto all image frames yielded the arterial timeactivity curve C A (t). A similar approach was used for right ventricular cavity and pulmonary artery, thereby providing a time-activity curve for the pulmonary circulation C V (t) (17) . For [
11 C]docetaxel, the plasma IDIF was obtained by multiplying C A (t) with a sigmoid function describing the plasma/whole blood ratio over time. The correction for plasma/whole blood ratio was based on either arterial or venous sampling.
Delineation of tumors
Tumors were defined on the low-dose CT scans by an experienced nuclear medicine physician (E.F.C.) who was blinded to patients' history and outcome. To this end, all low-dose CT images were converted to ECAT 7 format and tumor VOIs were drawn using the CAPP software package (CTI/Siemens). Finally, these VOIs were projected onto the dynamic images of the corresponding [ 15 
Analysis of tumor perfusion
Kinetic analysis of data was carried out using dedicated programs written within the software environment Matlab (The MathWorks Inc.). The standard single-tissue compartment model was used to derive tumor perfusion from [
15 O]H 2 O kinetics, applying corrections for both arterial and pulmonary artery blood volume (18):
where C T (t) represents measured tissue [
15 O]H 2 O concentration as function of time, F perfusion, V A arterial blood volume, V V pulmonary circulation blood volume, and V T the volume of distribution or partition coefficient of water.
Using nonlinear regression, tumor time-activity curves were fitted to this single-tissue compartment model using IDIF as arterial input function (17) . The correction for pulmonary circulation blood volume was included, as it improved the quality of the fits without affecting tumor perfusion values (17) .
Analysis of [
11 C]docetaxel kinetics in tumors To develop a kinetic model and validate the use of a noninvasive procedure for quantification of [ 11 C]docetaxel data, only lesions with a volume !4 cm 3 were considered. The generated time-activity curves of arterial blood and tumor tissue were entered into the analysis (Fig. 1) . First, nonlinear regression analysis was applied to fit the tumor time-activity curves of [
11 C]docetaxel to a two-tissue reversible (4 rate constants) and a two-tissue irreversible (3 rate constants) compartment model, both including a blood volume parameter and using the BSIF derived plasma input function. Akaike and Schwarz criteria (19, 20) were used to determine which model best described [ 11 C]docetaxel kinetics in tumors.
The two-tissue compartment model ( Fig. 1 ) describes the total tissue signal (C T ) by the following equation:
where C 1 (t) and C 2 (t) are concentrations in 1st and 2nd compartment, respectively. Kinetics in both compartments are given by the following differential equations:
where C P is arterial plasma concentration, K 1 the rate constant for transport from plasma to tumor, k 2 the rate ]docetaxel were obtained from arterial blood sampling or an IDIF. For the latter, VOIs were drawn over the ascending aorta in a frame in which the first pass of the bolus was best visualized. In addition, a tumor VOI was defined on the low-dose CT scan. Finally, aorta VOI and tumor VOI were projected onto the dynamic images of the corresponding [ 11 C]docetaxel scan, thereby generating time-activity curves. B, time-activity curves of arterial blood and tumor tissue were entered into two-tissue compartment modeling. To this end, either BSIF or IDIF was entered into the analysis as arterial input function. C, schematic diagram of a two-tissue compartment model. The concentration (C) in the tumor consists of [
11 C]docetaxel in compartments 1 (C 1 ) and 2 (C 2 ), representing free and bound [ 11 C]docetaxel, respectively. Kinetics of [ 11 C]docetaxel in tumor tissue is regulated by input from plasma (C P ) and four kinetic rate constants K 1 , k 2 , k 3 , and k 4 . K 1 is the rate constant describing transport from plasma to tumor, k 2 is the rate constant for clearance from tumor to plasma, and k 3 and k 4 are kinetic rate constants describing exchange between the two tumor compartments. For the irreversible two-tissue compartment model k 4 ¼ 0. VOI, volume of interest; BSIF, blood sampler derived input function; IDIF, image derived input function.
constant for clearance from tumor to plasma, and k 3 and k 4 kinetic rate constants describing exchange between 1st and 2nd compartment.
For the irreversible two-tissue compartment model, k 4 is 0. In this case the net influx rate constant K i can be calculated:
In case of irreversible uptake, both robustness and simplicity of the K i estimation can be improved by using the Patlak method (21). The Patlak plot is a linearization of the compartmental equations, and is given by:
where the intercept V 0 represents the initial volume of distribution. K i is now given by the slope of the linear part of the curve. The schematic diagram in Supplementary Fig. S1 illustrates the various steps that were carried out to develop a simplified procedure suitable for clinical implementation of [ 11 C]docetaxel studies. After validation of a simplified kinetic analysis (i.e., Patlak analysis), use of IDIF was compared with use of BSIF. Next, the use of discrete venous rather than arterial samples to correct IDIF for the time course of the plasma/whole blood ratio was investigated. Finally, the least invasive procedure was used to determine test-retest variability of [ 
Statistics
Statistical analysis was carried out using SPSS software (SPSS for Windows 16.0, SPSS, Inc.). Correlations were explored using the Spearman's correlation coefficient. Level of agreement was assessed using the intraclass correlation coefficient with a 2-way random model and Bland-Altman analysis (22) . The Mann-Whitney test was used to compare between groups.
Results
[ 11 C]docetaxel kinetics in blood
Initially, the plasma/whole blood ratio was >1, but it rapidly decreased to values <1 from 15 minutes onward ( Supplementary Fig. S2A ). There was high correlation between plasma/whole blood ratios obtained from arterial and venous sampling (Spearman's r ¼ 0.970; P < 0.001; n ¼ 169). In all patients, there was rapid systemic clearance Fig. S2B ). This precluded reliable high performance liquid chromatography (HPLC) measurements of radiolabeled metabolites of [ 11 C]docetaxel beyond 15 minutes after injection. Over the first 15 minutes, HPLC chromatograms did not reveal any radiolabeled metabolites and no radioactivity was measured in the solid-phase-extraction-rinsing fraction. Due to this rapid clearance of [ 11 C]docetaxel, calibration of the BSIF was not reliable at time points > 10 minutes after injection. Therefore, only the first 10 minutes of data were used for further analysis.
Quantification of [
11 C]docetaxel kinetics in tumors [ 11 C]docetaxel accumulated in lung cancer lesions (Fig. 2) . Fig. 2D shows a representative time-activity curve of [ 11 C]docetaxel in lung cancer. In the 17 patients who underwent arterial blood sampling, a total of 15 lesions had a volume !4 cm 3 . As a result, 15 lesions were eligible for validation of a simplified method for the analysis of [ 11 C]docetaxel PET/CT scans. According to both Akaike and Schwarz criteria, the irreversible two-tissue compartment model was the kinetic model of choice for 14 out of 15 lesions.
The irreversible behavior of [ 11 C]docetaxel kinetics was confirmed by Patlak plots, which became linear soon after injection (Fig. 2E) . The Patlak method showed the most robust values for K i , whereas the individual microparameters K 1 , k 2 , and k 3 showed relative large standard errors, which are due to noise levels of tissue tracer kinetics.
Validation of a less invasive procedure
Patlak and nonlinear regression analyses of [ 11 C]docetaxel data produced comparable K i values (Spearman's r ¼ 0.979; P < 0.001; Fig. 3A) . Therefore, the more robust and faster Patlak method was used in further analyses. Although K i values were lower for ascending aorta derived IDIF than those for corresponding BSIF (Fig. 3B) , correlation between both sets of K i values was high (Spearman's r ¼ 0.946; P < 0.001). Use of venous and arterial samples to correct IDIF for plasma/whole blood ratios resulted in comparable K i values (Spearman's r ¼ 0.986; P < 0.001; Fig. 3C ). According to the Patlak method, the median K i values were 0.011 mLÁcm ) for BSIF, IDIF using arterial samples and IDIF using venous samples, respectively.
Finally, using IDIF (with plasma/whole blood corrections based on venous samples) in the test-retest analysis showed good reproducibility for K i (Fig. 3D) Fig. 4 ).
Correlation with tumor size
Overall, 32 lesions (22 primary tumors and 10 metastases) could be identified on the corresponding low-dose CT scans. In these lesions, the K i of [ ), this difference did not reach statistical significance (Mann-Whitney, P ¼ 0.093; Fig. 5B ). However, when K i was normalized for tumor perfusion, there was no difference between patients who were pretreated with dexamethasone and patients who were not pretreated (Mann-Whitney, P ¼ 0.297). When analyzed separately, the association between K i of [ ) in patients with and without dexamethasone premedication, respectively (Mann-Whitney, P ¼ 0.724; Fig. 5C ).
[ 11 C]docetaxel kinetics and clinical outcome
Seven non-small cell lung cancer patients were scheduled for docetaxel therapy following this PET study. Three of those were treated simultaneously with platinumbased agents. All patients received premedication with In the first evaluation, the median change in the longest diameter of these lesions was 4% (range, À6% to 100%). The K i of [ 11 C]docetaxel was negatively associated with the change in tumor size (Spearman's r ¼ À0.803; P ¼ 0.002). Tumors with a K i value > 0.0073 mLÁcm
À3
Ámin
À1 had a significantly better response than tumors with a lower K i value (Mann-Whitney, P ¼ 0.007). Figure 6 shows an example of a patient with stable disease and another patient with progressive disease. The change in tumor size was not significantly affected by additional treatment with platinum-based agents (Mann-Whitney, P ¼ 0.073).
Discussion
Docetaxel is an effective drug for the treatment of patients with several cancers, including non-small cell lung cancer (23, 24) . However, tumor resistance to docetaxel therapy remains a major challenge. Quantitative 11 C]docetaxel clearance was measured in these patients. In the few patients who were subsequently treated with docetaxel, [ 11 C]docetaxel uptake in tumors seemed to be associated with treatment outcome.
[ 11 C]docetaxel showed fast kinetics, reflected by the rapid clearance of radioactivity from blood. Consequently, only 10 minutes of blood data could be used, as input functions were not reliable at later times. In addition, 10-15 minutes after injection already more than 50% of the total administered activity was located in the liver. Rapid clearance of [ 11 C]docetaxel from blood and high [ 11 C]docetaxel uptake in liver likely reflect extensive metabolism of docetaxel. Nevertheless, no radiolabeled metabolites of [ 11 C]docetaxel were detected, obviating the need to correct the arterial input function for radiolabeled metabolites. In the liver microsomes, docetaxel is metabolized mainly by the cytochrome P450 enzyme CYP3A4 (25) . Hepatic transformation and subsequent biliary excretion into feces is known to account for $80% of the elimination of an administered therapeutic dose (26) . In addition, active efflux by ABCB1 in intestine and biliary system represents an alternative pathway of docetaxel elimination (27) .
K i of [ 11 C]docetaxel in lung cancer was variable and highly related to tumor perfusion, but not to tumor size. 
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Quantification of [ Tumor perfusion also was variable, which may reflect interindividual differences in tumor vasculature. The tumor vasculature itself may also limit [ 11 C]docetaxel delivery to tumors, as it is structurally and functionally abnormal, consisting of leaky and dilated vessels that result in increased interstitial fluid pressure and reduced drug penetration (28) . Limited drug penetration in tumors is an important mechanism of tumor resistance to docetaxel therapy. A previous study in tumor xenografts showed that docetaxel accumulation was limited to the first $100 mm around a blood vessel, with little drug reaching a distance of 100 to 150 mm (29) . Although a larger tumor size may result in reduced perfusion in the central part, consequently leading to lower average perfusion values, no associations between tumor size and [
11 C]docetaxel kinetics or tumor perfusion were found.
The high correlation between tumor perfusion and [ 11 C]docetaxel uptake suggests that tumor uptake of [ 11 C]docetaxel primarily depends on tumor perfusion. Consequently, administration of drugs that change tumor perfusion, e.g., antiangiogenic agents, may have significant effects on docetaxel delivery to tumors, possibly affecting its efficacy. The methodology developed here, measuring both perfusion and docetaxel kinetics, provides a noninvasive means to investigate effects of antiangiogenic drugs on both tumor perfusion and docetaxel delivery. This, in turn, may lead to optimized scheduling of drugs, thereby enhancing antitumor efficacy of combination therapy.
Next to tumor perfusion, intracellular binding of (34, 35) . Because dexamethasone is administered routinely as premedication for docetaxel, more studies are required to further clarify the effects of dexamethasone and its scheduling on perfusion and docetaxel kinetics in tumors.
PET using radiolabeled anticancer drugs may be valuable for predicting outcome prior to start of treatment and, as such, it may be an important tool for individualized treatment planning. Human PET studies with radiolabeled anticancer drugs (36) , have shown that high tumor concentrations of the radiolabeled drug were associated with improved tumor response. Although the present study was not designed to predict tumor response to docetaxel therapy, the finding in the limited number of docetaxel-treated patients suggests that variable [ 11 C]docetaxel kinetics in tumors may reflect differential sensitivity to docetaxel therapy. Ideally, only patients scheduled for docetaxel treatment should have been selected for the present study. In the present validation study, however, three cannulas including one for arterial sampling were required and therefore also patients scheduled for other therapies were included. The noninvasive approach developed in this study now provides a means to investigate the relationship between [ 11 C]docetaxel uptake and response to docetaxel treatment in larger cohorts of lung cancer patients and in patients with other tumors located in the thoracic region such as locally advanced breast cancer. Although microdosing prevents patients from drug-induced toxicities associated with therapeutic doses, it has potential limitations, as the kinetic behavior of tracer and therapeutic doses differ. Therefore, further PET studies using [ 11 C]docetaxel during docetaxel therapy are also needed to assess whether tumor kinetics are dose dependent.
In conclusion, full quantification of [ 11 C]docetaxel kinetics in lung cancer patients using a noninvasive PET based approach is feasible. Tumor kinetics of [ 11 C]docetaxel were highly variable and strongly related to tumor perfusion. In addition, uptake of [ 11 C]docetaxel in tumors was reduced in patients pretreated with dexamethasone. Variable [
11 C]docetaxel kinetics in tumors may reflect differential sensitivity to docetaxel therapy. The findings of this study warrant further clinical studies investigating the predictive value of initial [ 11 C]docetaxel uptake and the effects of comedication on docetaxel kinetics in tumors.
